中国实用外科杂志2017，Vol.37Issue(1)：18-20,3.DOI:10.19538/j.cjps.issn1005-2208.2017.01.06
美国代谢与减重手术学会2016年最新立场声明解读
Interpretation of the updated position statements on bariatric surgery and implantable devices from American Society for Metabolic and Bariatric Surgery in 2016
申晓军 1郑成竹 1印慨1
作者信息
- 1. 第二军医大学附属长海医院普外科，上海200433
- 折叠
摘要
Abstract
The American Society for Metabolic and Bariatric Surgery (ASMBS) has issued a series of position statements in April 2016 in response to numerous inquiries made to the Society by patients, physicians, hospitals, the media, and others regarding the metabolic and bariatric surgery and two kinds of implantable devices. Data suggest that metabolic and bariatric surgery may improve survival and longevity, relative to the nonsurgical usual care treatment of individuals with class Ⅱ and Ⅲ obesity. The Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) provided an overview of the available evidence regarding the clinical utility, efficacy, and safety of endoscopically placed intragastric balloon for obesity and related diseases. The technology of intragastric balloons and its application in the treatment of obesity were approved by ASMBS and SAGES. A new device for weight loss called vagal blocking therapy for obesity (VBLOC) was approved for patients with a body mass index (BMI) 35 to 45 kg/m2. Based on current evidence available, the long-term efficacy and adverse events of this new technology should be further established.关键词
肥胖症/代谢和减重手术/胃内球囊/迷走神经阻断治疗Key words
obesity/metabolic and bariatric surgery/intragastric balloon/vagal blocking therapy分类
医药卫生引用本文复制引用
申晓军,郑成竹,印慨..美国代谢与减重手术学会2016年最新立场声明解读[J].中国实用外科杂志,2017,37(1):18-20,3.
